Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Goitre

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Goitre. Displaying page 1 of 1.
    EudraCT Number: 2008-002123-93 Sponsor Protocol Number: MINGO Start Date*: 2009-07-30
    Sponsor Name:Johannes Gutenberg-Universität
    Full Title: Mycophenolate sodium in Graves’ orbitopathy
    Medical condition: Graves' orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065624 Graves-Basedow disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014361-14 Sponsor Protocol Number: 577/09 Start Date*: 2010-01-13
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: EVALUATION OF FEASIBILITY OF RITUXIMAB BY INTRALESIONAL INJECTION IN PATIENTS WITH GRAVES OPHTALMOPATHY
    Medical condition: GRAVES OPHTALMOPATHY
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065624 Graves-Basedow disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005564-41 Sponsor Protocol Number: CCFZ533X2205 Start Date*: 2016-06-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label study to evaluate the safety and efficacy of 12 week treatment with CFZ533 in patients with Graves' disease
    Medical condition: Graves' disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10018706 Graves' disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002555-33 Sponsor Protocol Number: 2006.415 Start Date*: 2007-03-14
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Comparaison de l'efficacité et de la tolérance de différentes doses de méthylprednisolone administrées par voie intraveineuse dans le traitement des formes actives et de sévérité moyenne d'orbitopa...
    Medical condition: orbitopathie basedowienne
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015679 Exophthalmic goiter LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001910-40 Sponsor Protocol Number: OPHT-120312 Start Date*: 2012-06-06
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: The effect of intravenous glucocorticoids on the tearfilm in eyes with thyroid-associated ophthalmopathy
    Medical condition: Thyroid-associated ophthalmopathy (TAO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10065624 Graves-Basedow disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022840-19 Sponsor Protocol Number: SEBA Start Date*: 2011-12-30
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: A monocentric, randomized, placebo-controlled double-blind clinical trial to assess the efficacy of Selenium in Morbus Basedow
    Medical condition: Morbus Basedow
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10004161 Basedow's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002894-27 Sponsor Protocol Number: IMVT-1401-2501 Start Date*: 2023-04-03
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD)
    Medical condition: Graves` disease
    Disease: Version SOC Term Classification Code Term Level
    26.0 10014698 - Endocrine disorders 10018706 Graves' disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001317-33 Sponsor Protocol Number: STAGO Start Date*: 2020-05-14
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A Phase II, open-label, ophthalmological external investigator-blinded, single-center, randomized, superiority, no profit, pilot clinical trial to evaluate the effects of atorvastatin on Graves' Or...
    Medical condition: Graves’ orbitopathy is a disabling and disfiguring disease affecting the eyes observed in approximately 25-30% of patients with Graves’ disease. Its clinical manifestations include exophthalmos, in...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10004161 Basedow's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001941-11 Sponsor Protocol Number: 2021-1798 Start Date*: 2021-09-09
    Sponsor Name:Rijnstate hospital
    Full Title: Ultrasound-guided radiofrequency ablation versus radioactive iodine as treatment for hyperthyroidism caused by solitary autonomous thyroid nodules.
    Medical condition: Patients > 18 years with (subclinical) hyperthyroidism caused by a solitary hyperactive thyroid nodules, either as a solitary hyperactive node in an otherwise normal thyroid gland or as a single hy...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004860 10043753 Thyroid nodule (toxic) LLT
    20.0 100000004860 10043791 Thyrotoxicosis from ectopic thyroid nodule LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004451-35 Sponsor Protocol Number: MRTSH01505 Start Date*: 2007-03-13
    Sponsor Name:Genzyme Europe BV
    Full Title: Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multi...
    Medical condition: Nodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the nor...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043808 Thyrotropin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005606-30 Sponsor Protocol Number: CAM-THY Start Date*: 2012-04-25
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY
    Medical condition: This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10058948 Nephritis autoimmune PT
    14.1 10014698 - Endocrine disorders 10049046 Autoimmune thyroiditis PT
    14.1 10021428 - Immune system disorders 10061664 Autoimmune disorder PT
    14.1 10014698 - Endocrine disorders 10068004 Autoimmune hyperthyroidism LLT
    14.1 10005329 - Blood and lymphatic system disorders 10050245 Autoimmune thrombocytopenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:29:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA